Search
alpelisib (Piqray)
Indications:
- treatment or postmenopausal women & men, with ER & PR-positive, HER2-negative, PIK3CA-mutated, advanced or metastatic breast cancer
* used in combination with fulvestran
Monitor:
- serum glucose, hemoglobin A1c
Adverse effects:
- hyperglycemia, increase in serum creatinine, hypocalcemia
- lymphopenia, anemia, prolonged aPTT prolonged
- elevated liver enzymes, increase in serum lipase
- diarrhea, nausea/vomiting, decreased appetite, stomatitis
- pneumonitis/interstitial lung disease
- weight loss, fatigue
- rash, hair loss
- potentially severe skin reactions
- Stevens-Johnson Syndrome, erythema multiforme, toxic epidermal necrolysis
Laboratory:
- used in combination with approved the companion diagnostic test, therascreen PIK3CA RGQ PCR Kit*
* detects the PIK3CA mutation in a tissue &/or a liquid biopsy
* patients who are negative by the therascreen test using a liquid biopsy should undergo tumor biopsy for PIK3CA mutation testing.
Mechanism of action:
- PIK3 inhibitor
General
small inhibitory antineoplastic agent (ib drug)
Database Correlations
PUBCHEM cid=56649450
References
- FDA News Release. May 24, 2019
FDA approves first PI3K inhibitor for breast cancer
https://www.fda.gov/news-events/press-announcements/fda-approves-first-pi3k-inhibitor-breast-cancer